Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
1039- Fuc,    Anti-Proliferative and Pro-Apoptotic vLMW Fucoidan Formulas Decrease PD-L1 Surface Expression in EBV Latency III and DLBCL Tumoral B-Cells by Decreasing Actin Network
- in-vitro, NA, NA
TumCP↓, Apoptosis↑, PD-L1↓,
1114- Fuc,    The Potential Effect of Fucoidan on Inhibiting Epithelial-to-Mesenchymal Transition, Proliferation, and Increase in Apoptosis for Endometriosis Treatment: In Vivo and In Vitro Study
- vitro+vivo, NA, NA
tumCV↓, TumCMig↓, VEGF↓, EMT↓, Apoptosis↑,
1038- Fuc,  immuno,    Fucoidan enhances the anti-tumor effect of anti-PD-1 immunotherapy by regulating gut microbiota.
- in-vivo, BC, NA
GutMicro↑, T-Cell↑, Treg lymp↓,
1155- Fuc,    The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations
- Review, NA, NA
*toxicity↓, Casp3↑, Casp7↑, Casp8↑, Casp9↑, VEGF↓, angioG↓, PI3K↓, Akt↓, PARP↑, Bak↑, BID↑, Fas↑, Mcl-1↓, survivin↓, XIAP↓, ERK↓, EMT↓, EM↑, IM↓, Snail↓, Slug↓, Twist↓,
4023- FulvicA,    Shilajit (Mumio) Elicits Apoptosis and Suppresses Cell Migration in Oral Cancer Cells through Targeting Urokinase-type Plasminogen Activator and Its Receptor and Chemokine Signaling Pathways
- in-vitro, Oral, NA
tumCV↓, selectivity↑, Apoptosis↑, uPA↓, TumCMig↓, Dose↝, CXCc↓,
4022- FulvicA,  Chemo,    Shilajit potentiates the effect of chemotherapeutic drugs and mitigates metastasis induced liver and kidney damages in osteosarcoma rats
- in-vivo, OS, NA
AST↓, ALAT↓, ALP↓, Bil↝, creat↓, uricA↓, ChemoSen↑, chemoP↑,
4024- FulvicA,    ANTI-CARCINOGENIC ACTIVITY OF SHILAJIT REGARDING TO APOPTOSIS ASSAY IN CANCER CELLS: A SYSTEMATIC REVIEW OF IN-VITRO STUDIES
- Review, Var, NA
*Inflam↓, *antiOx↑, TumCG↓, tumCV↓, ROS↑, ChemoSen↑, toxicity↝,
4025- FulvicA,    Mumio (Shilajit) as a potential chemotherapeutic for the urinary bladder cancer treatment
- in-vitro, Bladder, T24/HTB-9 - Review, AD, NA
tumCV↓, selectivity↑, TumCCA↑, other↝, *neuroP↑, *memory↑, *tau↓, *other↝, *lipid-P↓, *VitC↑, *antiOx↑,
4026- FulvicA,    Shilajitin Cancer Treatment: Probable Mode of Action
- Review, Var, NA
*Inflam↓, *antiOx↑, Dose↝,
4027- FulvicA,    Mummy Induces Apoptosis Through Inhibiting of Epithelial-Mesenchymal Transition (EMT) in Human Breast Cancer Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7 - in-vitro, Nor, MCF10
tumCV↓, selectivity↑, TGF-β↓, Twist↓, NOTCH1↓, CTNNB1↓, Src↓, E-cadherin↑, EMT↓, TumMeta↓, BioAv↑,
4028- FulvicA,    Mineral pitch induces apoptosis and inhibits proliferation via modulating reactive oxygen species in hepatic cancer cells
- in-vitro, Liver, HUH7
Apoptosis↑, TumCP↓, ROS↑, NO↑, Dose↝, MMP↓, Cyt‑c↑, SOD↓, Catalase↓, GSH↑, lipid-P↑, miR-21↓, miR-22↑,
4029- FulvicA,  Chemo,    Shilajit mitigates chemotherapeutic drug-induced testicular toxicity: Study on testicular germ cell dynamics, steroidogenesis modulation, and Nrf-2/Keap-1 signaling
- in-vivo, Var, NA
*other↑, *PCNA↑, *SOD↑, *lipid-P↓, *NRF2↑, *Keap1↓, *chemoP↑,
4030- FulvicA,    Therapeutic Potential of Fulvic Acid in Chronic Inflammatory Diseases and Diabetes
- Review, NA, NA
*Inflam↓, TNF-α↓, *COX2/PTGS2↓, *PGE2↓, *ROS↓, *GutMicro↑, *BioEnh↑, *BioEnh↑, *SOD↑, *Catalase↑, *GPx↑,
4018- FulvicA,  Fe,    Inhibitory Impacts of Fulvic Acid-Coated Iron Oxide Nanoparticles on the Amyloid Fibril Aggregations
- in-vivo, AD, NA
*Inflam↓, *Aβ↓,
4017- FulvicA,    Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer's disease
- NA, AD, NA
*cognitive↑, *tau↓,
4019- FulvicA,    Can nutraceuticals prevent Alzheimer's disease? Potential therapeutic role of a formulation containing shilajit and complex B vitamins
- Review, AD, NA
*neuroP↑,
4016- FulvicA,    Shilajit: A Natural Phytocomplex with Potential Procognitive Activity
- Review, AD, NA
*tau↓, *AntiAge↑, *Strength↑, *Dose↝, *BioAv↑, *antiOx↑, *memory↑, *Inflam↓, *cognitive↑, *neuroP↑, *toxicity↝, *toxicity↑,
4020- FulvicA,    Natural products as a rich source of tau-targeting drugs for Alzheimer’s disease
- in-vitro, AD, NA
*tau↓, *cognitive↑,
4021- FulvicA,    Scaling the Andean Shilajit: A Novel Neuroprotective Agent for Alzheimer’s Disease
- in-vitro, AD, NA
*tau↓, *neuroP↑,
1283- GA,  immuno,    Gallic acid induces T-helper-1-like Treg cells and strengthens immune checkpoint blockade efficacy
- vitro+vivo, CRC, NA
p‑STAT3↓, Treg lymp↓, FOXP3↓, CD8+↑, IFN-γ↑,
1300- GA,  PacT,  carbop,    Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line
- in-vitro, BC, MCF7
TumCCA↑, Apoptosis↑, P53↑, BAX↑, Casp3↑, Bcl-2↓,
1624- GA,    Anticancer Effect of Pomegranate Peel Polyphenols against Cervical Cancer
- in-vitro, Cerv, NA
ROS↑, Dose∅, MMP↓, GSH↑,
1773- GA,    Impact of Gallic Acid on Gut Health: Focus on the Gut Microbiome, Immune Response, and Mechanisms of Action
- Review, Var, NA
antiOx↑, AntiCan↑, Inflam↓, GutMicro↑, BioAv↝, BioAv↓, BioAv↑, TumMeta↓,
1091- GA,    Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells
- in-vitro, Cerv, HeLa - in-vitro, Cerv, HTB-35
tumCV↓, TumCP↓, ADAM17↓, EGFR↓, p‑Akt↓, p‑ERK↓,
1115- GA,    Gallic acid alleviates gastric precancerous lesions through inhibition of epithelial mesenchymal transition via Wnt/β-catenin signaling pathway
- in-vivo, GC, GES-1
TumCP↓, TumCCA↑, Wnt/(β-catenin)↓, EMT↓,
1086- GA,    Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation
- in-vitro, AML, K562
tumCV↓, TumCCA↑, P21↑, p27/CDKN1B↑, cycD1/CCND1↓, cycE/CCNE↓, Bax:Bcl2↑, Cyt‑c↑, cl‑PARP↓, DNAdam↑, Casp3↑, FASN↓, Casp8↑,
1065- GA,    Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression
- vitro+vivo, Pca, NA
tumCV↓, MMP↓, DNAdam↑, HDAC1↓, HDAC2↓, PCNA↓, cycD1/CCND1↓, cycE1↓, P21↑, TumVol↓,
987- GA,    Targeting Aerobic Glycolysis: Gallic Acid as Promising Anticancer Drug
- in-vitro, GBM, AMGM - in-vitro, Cerv, HeLa - in-vitro, BC, MCF7
LDH↓, TumCG↓,
997- GA,    The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells
- in-vitro, Lung, A549 - in-vitro, Lung, H292 - in-vitro, Nor, HUVECs
PD-L1↓, p‑EGFR↓, p‑PI3K↓, p‑Akt↓, P53↑, miR-34a↑, *toxicity↓,
947- GA,    Gallic acid, a phenolic compound, exerts anti-angiogenic effects via the PTEN/AKT/HIF-1α/VEGF signaling pathway in ovarian cancer cells
- in-vitro, Ovarian, OVCAR-3 - in-vitro, Melanoma, A2780S - in-vitro, Nor, IOSE364 - Human, NA, NA
TumCG↓, VEGF↓, angioG↓, p‑Akt↓, Hif1a↓, PTEN↑, BioAv↑, *toxicity↓,
7034- GA,  RES,    The Growth Inhibitory Effect of Resveratrol and Gallic Acid on Prostate Cancer Cell Lines through the Alteration of Oxidative Stress Balance: The Interplay between Nrf2, HO-1, and BACH1 Genes
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145
TumCG↓, ROS↓, SOD↑, GPx↑, Catalase↑, GSR↑, GSH↑, HO-1↑, NRF2↑,
7041- GA,    Gallic acid suppresses the progression of clear cell renal cell carcinoma through inducing autophagy via the PI3K/Akt/Atg16L1 signaling pathway
- vitro+vivo, RCC, 786-O - in-vitro, RCC, ACHN - in-vitro, Nor, HK-2
selectivity↑, TumCP↓, TumCMig↓, TumCI↓, TumCCA↑, TumVol↓, TumW↓, Ki-67↓, MMP9↓, TumAuto↑, LC3B-II↓, Beclin-1/ATG6↓, p62↑,
7035- GA,    Gallic acid attenuates LPS-induced inflammation in Caco-2 cells by suppressing the activation of the NF-κB/MAPK signaling pathway
- in-vitro, IBD, Caco-2
*Inflam↓, *antiOx↑, *CLDN1↓, *OCLN↓, *ZO-1↓, *IL6↓, *IL1β↓, *TNF-α↓, *BAX↓, *BAD↓, *Casp3↓, *Casp8↓, *ROS↓, *SOD↑, *Catalase↑, *GSH↑, *TJ↑, *Apoptosis↓, *NF-kB↓, *MAPK↓,
7037- GA,  Chit,    Gallic acid-loaded chitosan nanoparticles enhance the DNA damage and apoptotic features through inhibiting flap endonuclease-1 in triple-negative breast cancer cells
- in-vitro, BC, MDA-MB-231
DNAdam↑, Apoptosis↑, FEN1↓, selectivity↑, ROS↑, DNAdam↑, PARP1↑, TumCP↓, p‑PI3K↓, Akt↓, cycD1/CCND1↓, BAX↑, Casp3↑,
7038- GA,    Gallic acid for cancer therapy: Molecular mechanisms and boosting efficacy by nanoscopical delivery
- Review, Var, NA
PI3K↓, Akt↓, ChemoSen↑, BioAv↑,
7040- GA,    Effects of gallic acid on acrylamide-induced endoplasmic reticulum stress, neuroinflammation and neuronal apoptosis in rats
- Trial, AD, NA
*SOD↑, *GSH↑, *GPx↑, *Catalase↑, *MDA↓, *TNF-α↓, *IL1β↓, *BAX↓, *Casp3↓, *BDNF↑, *NRF2↑, *HO-1↑,
7042- GA,    Gallic acid reduces cell growth by induction of apoptosis and reduction of IL-8 in HepG2 cells
- in-vitro, Liver, HepG2
*Inflam↓, *AntiTum↑, *antiOx↑, TumCP↓, IL8↓, IL10↑, IL12↑, Apoptosis↑,
7043- GA,    Gallic acid-induced lung cancer cell death is related to glutathione depletion as well as reactive oxygen species increase
- in-vitro, Lung, Calu-1 - in-vitro, Lung, A549
TumCG↓, MMP↓, ROS↑, GSH↓, eff↑, eff↓, eff↑, mtDam↑, Ca+2↑,
7044- GA,  QC,    Inhibitory effects of gallic acid and quercetin on UDP-glucose dehydrogenase activity
- in-vitro, BC, MCF7
UGDH↓, UGDH↓, TumCP↓, Dose↑, *BioAv↓, eff?,
7046- GA,    Gallic acid: A promising anti-non-small cell lung cancer compound targeting early growth response protein-1 for apoptosis and ferroptosis
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, H1299
TumCP↓, TumCCA↑, TumCMig↓, TumCI↓, Apoptosis↑, Ferroptosis↑, THBS1↓, EGR1↓, TGF-β1↓, SMAD2↓, SMAD3↓, GPx4↓, ROS↑, i-MDA↑, i-Iron↑,
7047- GA,    Gallic acid-conjugated 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone induces apoptosis and downregulates PI3K/Akt signaling through VEGFR-2 targeting in non-small cell lung cancer (NSCLC)
- in-vitro, NSCLC, A549
TumCP↓, selectivity↑, AKT1↓, EP4/PTGER4↓, PDK1 / PDPK1↓, VEGFR2/KDR/Flk1↓,
7048- GA,    Natural bioactive gallic acid shows potential anticancer effects by inhibiting the proliferation and invasiveness behavior in human embryonic carcinoma cells
- in-vitro, Var, NA
AntiCan↑, TumCCA↑, angioG↓, TumCMig↓, TumMeta↓, CSCs↓, Apoptosis↑, P21↑, P53↑, p27/CDKN1B↑, CDK4↓, cycE/CCNE↓, cycD1/CCND1↓, SOX2↓, Nanog↓, OCT4↓, ROS↑, DNAdam↑, BRCA1↑, ATM↑, CHK1↑, Chk2↑, Histones↑, TumCI↓, MMPs↓, EGFR↓, JAK2↓, STAT5↓,
7049- GA,    Pharmacological effects of gallic acid in health and diseases: A mechanistic review
- Review, Var, NA
*antiOx↑, *Inflam↓, *antiNeop↑, *cardioP↑, *Bacteria↓, *AST↓, *ALAT↓, *ALP↓, *lipid-P↓, *GSH↑, *Catalase↑, *GPx↑, *GSTs↑, *Urea↓, *creat↓, tumCV↓, TumCCA↑, i-Ca+2↑, CDK1↑, Casp3↑, Casp8↑, Casp9↑, MMP↓, ROS↑, MMPs↓, *GastroP↑, *hepatoP↑, *ROS↓, *AChE↑,
7032- GA,  Cisplatin,    Gallic acid: a polyphenolic compound potentiates the therapeutic efficacy of cisplatin in human breast cancer cells
- in-vitro, BC, MCF7 - in-vitro, Nor, MCF10
ChemoSen↑, tumCV↓, Apoptosis↑, selectivity↑, *ROS↓, eff↑, *chemoP↑, Dose↝,
7033- GA,  OL,    Gallic Acid Enhances Olaparib-Induced Cell Death and Attenuates Olaparib Resistance in Human Osteosarcoma U2OS Cell Line
- in-vitro, OS, U2OS
tumCV↓, angioG↓, DNAdam↑, Apoptosis↑, cl‑PARP↓, Bcl-2↓, BAX↑, ROS↓, eff↑, TumCMig↓, VEGF↓, Casp9↑, P53↑, selectivity↑,
7031- GA,  Cisplatin,    Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non‑small cell lung cancer A549 cells via the JAK/STAT3 signaling pathway
- in-vitro, Lung, A549
TumCP↓, Apoptosis↑, BAX↑, Bcl-2↓, ChemoSen↑, JAK↓, STAT3↓,
7030- GA,    Gallic Acid Induces Apoptosis in Human Gastric Adenocarcinoma Cells
- in-vitro, GC, AGS
Fas↑, FasL↑, DR5↑,
7029- GA,    Gallic acid induces G1 phase arrest and apoptosis of triple-negative breast cancer cell MDA-MB-231 via p38 mitogen-activated protein kinase/p21/p27 axis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, HS587T - in-vitro, Nor, MCF10
AntiTum↑, tumCV↓, selectivity↑, TumCCA↑, cycD1/CCND1↓, CDK4↓, cycE/CCNE↓, CDK2↓, P21↑, p27/CDKN1B↑, Casp9↑, Casp3↑, ROS↑, mtDam↑, i-Ca+2↑, *ROS↓, *Apoptosis↓, TumCG↓,
7028- GA,    Gallic acid: Pharmacological activities and molecular mechanisms involved in inflammation-related diseases
- Review, Nor, NA
*toxicity↓, *Inflam↓, *NF-kB↓, AntiTum↑, Bacteria↓, *AntiDiabetic↑, *Obesity↓, *AntiBio↑, *Stroke↓, *NO↓, *PGE2↓, *IL6↓, *MAPK↓, *TNF-α↓, *IL1β↓, *MCP1/CCL2↓, *ICAM-1↓, *TIMP1↓,
7027- GA,    Pharmacokinetics of gallic acid and its relative bioavailability from tea in healthy humans
- Human, Nor, NA
AntiCan↑, *Inflam↓, *BioAv↑, *Half-Life↓, *eff↝,

Showing Research Papers: 4001 to 4050 of 8269
Prev Page 81 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

FEN1↓, 1,   UGDH↓, 2,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Bil↝, 1,   Catalase↓, 1,   Catalase↑, 1,   Ferroptosis↑, 1,   GPx↑, 1,   GPx4↓, 1,   GSH↓, 1,   GSH↑, 3,   GSR↑, 1,   HO-1↑, 1,   i-Iron↑, 1,   lipid-P↑, 1,   i-MDA↑, 1,   NRF2↑, 1,   ROS↓, 2,   ROS↑, 9,   SOD↓, 1,   SOD↑, 1,   uricA↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 5,   mtDam↑, 2,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AKT1↓, 1,   ALAT↓, 1,   FASN↓, 1,   Histones↑, 1,   LDH↓, 1,   PDK1 / PDPK1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 3,   p‑Akt↓, 3,   Apoptosis↑, 12,   Bak↑, 1,   BAX↑, 4,   Bax:Bcl2↑, 1,   Bcl-2↓, 3,   BID↑, 1,   Casp3↑, 6,   Casp7↑, 1,   Casp8↑, 3,   Casp9↑, 4,   Chk2↑, 1,   Cyt‑c↑, 2,   DR5↑, 1,   Fas↑, 2,   FasL↑, 1,   Ferroptosis↑, 1,   Mcl-1↓, 1,   p27/CDKN1B↑, 3,   survivin↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

miR-21↓, 1,   other↝, 1,   tumCV↓, 12,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↓, 1,   LC3B-II↓, 1,   p62↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,   BRCA1↑, 1,   CHK1↑, 1,   DNAdam↑, 6,   P53↑, 4,   PARP↑, 1,   cl‑PARP↓, 2,   PARP1↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↑, 1,   CDK2↓, 1,   CDK4↓, 2,   cycD1/CCND1↓, 5,   cycE/CCNE↓, 3,   cycE1↓, 1,   P21↑, 4,   TumCCA↑, 9,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 1,   CTNNB1↓, 1,   EMT↓, 4,   EP4/PTGER4↓, 1,   ERK↓, 1,   p‑ERK↓, 1,   HDAC1↓, 1,   HDAC2↓, 1,   miR-34a↑, 1,   Nanog↓, 1,   NOTCH1↓, 1,   OCT4↓, 1,   PI3K↓, 2,   p‑PI3K↓, 2,   PTEN↑, 1,   SOX2↓, 1,   Src↓, 1,   STAT3↓, 1,   p‑STAT3↓, 1,   STAT5↓, 1,   TumCG↓, 6,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↑, 1,   i-Ca+2↑, 2,   E-cadherin↑, 1,   EM↑, 1,   Ki-67↓, 1,   miR-22↑, 1,   MMP9↓, 1,   MMPs↓, 2,   Slug↓, 1,   SMAD2↓, 1,   SMAD3↓, 1,   Snail↓, 1,   TGF-β↓, 1,   TGF-β1↓, 1,   THBS1↓, 1,   Treg lymp↓, 2,   TumCI↓, 3,   TumCMig↓, 6,   TumCP↓, 11,   TumMeta↓, 3,   Twist↓, 2,   uPA↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 4,   EGFR↓, 2,   p‑EGFR↓, 1,   EGR1↓, 1,   Hif1a↓, 1,   NO↑, 1,   VEGF↓, 4,   VEGFR2/KDR/Flk1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CXCc↓, 1,   FOXP3↓, 1,   IFN-γ↑, 1,   IL10↑, 1,   IL12↑, 1,   IL8↓, 1,   Inflam↓, 1,   JAK↓, 1,   JAK2↓, 1,   PD-L1↓, 2,   T-Cell↑, 1,   TNF-α↓, 1,  

Cellular Microenvironment(tgid=17) ⓘ

ADAM17↓, 1,   IM↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 4,   BioAv↝, 1,   ChemoSen↑, 5,   Dose↑, 1,   Dose↝, 4,   Dose∅, 1,   eff?, 1,   eff↓, 1,   eff↑, 4,   selectivity↑, 9,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   Bil↝, 1,   BRCA1↑, 1,   creat↓, 1,   EGFR↓, 2,   p‑EGFR↓, 1,   GutMicro↑, 2,   Ki-67↓, 1,   LDH↓, 1,   PD-L1↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 3,   AntiTum↑, 2,   chemoP↑, 1,   toxicity↝, 1,   TumVol↓, 2,   TumW↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,   CD8+↑, 1,  
Total Targets: 173

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 1,   Stroke↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 7,   Catalase↑, 4,   GPx↑, 3,   GSH↑, 3,   GSTs↑, 1,   HO-1↑, 1,   Keap1↓, 1,   lipid-P↓, 3,   MDA↓, 1,   NRF2↑, 2,   ROS↓, 5,   SOD↑, 4,   VitC↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 2,   BAD↓, 1,   BAX↓, 2,   Casp3↓, 2,   Casp8↓, 1,   MAPK↓, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,   other↝, 1,  

DNA Damage & Repair(tgid=10) ⓘ

PCNA↑, 1,  

Migration(tgid=13) ⓘ

CLDN1↓, 1,   TIMP1↓, 1,   TJ↑, 1,   ZO-1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GastroP↑, 1,   OCLN↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   ICAM-1↓, 1,   IL1β↓, 3,   IL6↓, 2,   Inflam↓, 10,   MCP1/CCL2↓, 1,   NF-kB↓, 2,   PGE2↓, 2,   TNF-α↓, 3,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↑, 1,   BDNF↑, 1,   tau↓, 5,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 2,   BioEnh↑, 2,   Dose↝, 1,   eff↝, 1,   Half-Life↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   creat↓, 1,   GutMicro↑, 1,   IL6↓, 2,   Urea↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   AntiDiabetic↑, 1,   antiNeop↑, 1,   AntiTum↑, 1,   cardioP↑, 1,   chemoP↑, 2,   cognitive↑, 3,   hepatoP↑, 1,   memory↑, 2,   neuroP↑, 4,   Obesity↓, 1,   Strength↑, 1,   toxicity↓, 4,   toxicity↑, 1,   toxicity↝, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 74

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page